Revised NIH Definition of a Clinical Trial Explained

Overview

NIH continues to clarify its clinical trial definition and identification to support transparency and consistency in human research. The 2014 policy revision (NOT-OD-15-015) and the 2026 harmonization with the Common Rule (NOT-OD-26-063) are critical for investigators and research staff.

This article outlines what changed, why it matters, and how these changes impact NIH-funded research.

Why NIH Revised the Definition of a Clinical Trial

Before 2014, investigators struggled to determine if their studies met NIH’s definition of a clinical trial, especially in social, behavioral, and educational human subjects research. To fix this, NIH issued NOT-OD-15-015 to clarify which studies count as clinical trials.

• Improve the accuracy of NIH’s tracking and reporting.
• Ensure that appropriate oversight mechanisms are applied consistently.

NIH did not revise the definition to expand what qualifies as a clinical trial or change the definition of a Phase III clinical trial. The aim was greater clarity and consistency.

NIH clinical trials must meet additional requirements, including data and safety monitoring plans, milestone reporting, and ongoing NIH staff oversight. A clear definition helps investigators comply and supports proper NIH oversight.

The Revised NIH Definition of a Clinical Trial

Under NOT-OD-15-015, NIH defines a clinical trial as:

A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.

This definition contains four key elements:

• Research – The activity meets the Common Rule definition of research (45 CFR 46.102).
• Human subjects – The study involves human participants as defined by federal regulations.
• Prospective assignment – Subjects are assigned to intervention arms in advance according to a prespecified protocol.
• Intervention and outcome evaluation – The study evaluates the effects of an intervention on health-related biomedical or behavioral outcomes.

NIH provided clear examples of interventions (e.g., drugs, devices, behavioral strategies, and telemedicine delivery systems) and outcomes (e.g., physiological measures, psychological changes, and quality-of-life indicators) to help investigators apply the definition consistently.

NIH’s Original Definition of “Intervention”

As part of the 2014 revision, NIH defined an intervention as:

A manipulation of the subject or subject’s environment for the purpose of modifying one or more health-related biomedical or behavioral processes and/or endpoints.

This definition included a wide range of biomedical and behavioral research and was used across NIH funding, applications, and reporting.

However, at the time, this NIH-specific definition predated later regulatory changes to the federal Common Rule.

The Common Rule and Its Definition of “Intervention”

In 2018, the revised Common Rule (45 CFR 46, Subpart A) went into effect, defining an intervention as:

Both physical procedures by which information or biospecimens are gathered (e.g., venipuncture) and manipulations of the subject or the subject’s environment that are performed for research purposes.

This definition is broader and clearly includes data or specimen collection, even if not meant to modify health outcomes.

Harmonizing NIH Policy with the Common Rule

With NOT-OD-26-063, NIH now uses the Common Rule’s definition of “intervention” to decide if a study meets the NIH clinical trial definition.

This change was made to:

• Ensure consistency across federal agencies.
• Reduce confusion for institutions governed by both NIH policy and the Common Rule.
• Harmonize regulatory interpretation without changing NIH’s overall implementation approach.

NIH has already aligned its policies with the Common Rule, but officially adopting the Common Rule definition means investigators and institutions can use a single, consistent definition.

NIH will update its websites, forms, and guidance to reflect this change.

What This Means for Investigators and Institutions

This harmonization does not expand NIH’s definition of a clinical trial. Instead, it:

• Aligns NIH policy language with federal human subjects regulations.
• Reduces interpretive differences between NIH and institutional review boards (IRBs).
• Supports clearer study classification during proposal development and compliance review.

Investigators should use NIH’s decision tools, such as the “Is My Project a Clinical Trial, Basic Experimental Study Involving Humans (BESH), or an Observational Study?” guidance, to properly categorize their studies.

Correct classification remains critical, as it affects:

• Funding opportunity eligibility
• Application requirements
• Data and safety monitoring expectations
• Registration and reporting obligations

Key Takeaway

NOT-OD-15-015 and NOT-OD-26-063 show NIH’s ongoing effort to promote clarity, regulatory alignment, and accountability in human subjects research. By aligning the definition of “intervention” with the Common Rule and retaining key elements of the NIH clinical trial definition, NIH simplifies compliance without changing which research is subject to clinical trial oversight.